Show simple item record

dc.contributor.authorKissling, Esther
dc.contributor.authorValenciano, Marta
dc.contributor.authorPozo, Francisco
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorReuss, Annicka
dc.contributor.authorRizzo, Caterina
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorHorváth, Judit Krisztina
dc.contributor.authorBrytting, Mia
dc.contributor.authorDomegan, Lisa
dc.contributor.authorKorczyńska, Monika
dc.contributor.authorMeijer, Adam
dc.contributor.authorMachado, Ausenda
dc.contributor.authorIvanciuc, Alina
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorvan der Werf, Sylvie
dc.contributor.authorSchweiger, Brunhilde
dc.contributor.authorBella, Antonino
dc.contributor.authorGherasim, Alin
dc.contributor.authorFerenczi, Annamária
dc.contributor.authorZakikhany, Katherina
dc.contributor.authorO Donnell, Joan
dc.contributor.authorParadowska-Stankiewicz, Iwona
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorLazar, Mihaela
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorJohansen, Kari
dc.contributor.authorMoren, Alain
dc.descriptionDuring the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.en_US
dc.description.abstractDuring the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.
dc.publisherInfluenza and Other Respiratory Virusesen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.subjectcase-control studyen_US
dc.subjectinfluenza vaccineen_US
dc.subjectmulticentre studyen_US
dc.subjectvaccine effectivenessen_US
dc.title2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.en_US
dc.identifier.journalInfluenza and Other Respiratory Virusesen_US
dc.source.journaltitleInfluenza and other respiratory viruses

Files in this item

Kissling_et_al-2018-Influenza_ ...
Main Article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States